Aclaris Therapeutics (NASDAQ:ACRS) Given “Hold” Rating at Stifel Nicolaus

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “hold” rating reaffirmed by Stifel Nicolaus in a research report issued to clients and investors on Monday, November 13th, Benzinga reports.

A number of other research firms also recently weighed in on ACRS. Evercore ISI began coverage on shares of Aclaris Therapeutics in a research note on Tuesday, October 3rd. They set an “outperform” rating and a $22.00 price target for the company. StockNews.com initiated coverage on shares of Aclaris Therapeutics in a research note on Thursday, October 5th. They issued a “sell” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $38.00 target price on shares of Aclaris Therapeutics in a research note on Monday, October 9th. HC Wainwright reaffirmed a “buy” rating and issued a $43.00 target price on shares of Aclaris Therapeutics in a research note on Wednesday, October 4th. Finally, William Blair downgraded shares of Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, November 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.17.

Aclaris Therapeutics Price Performance

Shares of ACRS stock traded down $0.07 during trading hours on Monday, reaching $0.88. 3,980,512 shares of the company were exchanged, compared to its average volume of 1,559,218. Aclaris Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $18.79. The stock’s fifty day moving average is $5.44 and its two-hundred day moving average is $7.77. The company has a market cap of $62.58 million, a price-to-earnings ratio of -0.57 and a beta of 0.65.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.07. The company had revenue of $9.30 million for the quarter, compared to analyst estimates of $1.57 million. Aclaris Therapeutics had a negative net margin of 534.83% and a negative return on equity of 64.53%. Aclaris Therapeutics’s quarterly revenue was down 51.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.30) earnings per share. On average, research analysts anticipate that Aclaris Therapeutics will post -1.67 earnings per share for the current year.

Insider Transactions at Aclaris Therapeutics

In other news, insider Joseph Monahan sold 6,000 shares of the stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $5.08, for a total transaction of $30,480.00. Following the completion of the sale, the insider now owns 129,724 shares of the company’s stock, valued at $658,997.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Joseph Monahan sold 6,000 shares of the stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $5.08, for a total transaction of $30,480.00. Following the completion of the transaction, the insider now owns 129,724 shares in the company, valued at $658,997.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Loerop bought 14,705 shares of Aclaris Therapeutics stock in a transaction that occurred on Monday, August 28th. The shares were acquired at an average price of $6.80 per share, with a total value of $99,994.00. Following the acquisition, the insider now directly owns 21,688 shares of the company’s stock, valued at approximately $147,478.40. The disclosure for this purchase can be found here. 5.50% of the stock is owned by insiders.

Institutional Trading of Aclaris Therapeutics

A number of large investors have recently added to or reduced their stakes in ACRS. UBS Group AG lifted its stake in Aclaris Therapeutics by 41.4% in the second quarter. UBS Group AG now owns 2,406 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 704 shares during the last quarter. Royal Bank of Canada raised its position in shares of Aclaris Therapeutics by 31.6% in the second quarter. Royal Bank of Canada now owns 5,970 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 1,435 shares during the period. Point72 Middle East FZE bought a new position in shares of Aclaris Therapeutics in the fourth quarter valued at about $75,000. Corton Capital Inc. bought a new position in shares of Aclaris Therapeutics in the first quarter valued at about $84,000. Finally, State of Wyoming bought a new position in shares of Aclaris Therapeutics in the fourth quarter valued at about $87,000.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.